Your browser doesn't support javascript.
loading
CD73: A potential biomarker for anti-PD-1 therapy.
Beavis, Paul A; Slaney, Clare Y; Milenkovski, Nicole; Henderson, Melissa A; Loi, Sherene; Stagg, John; Kershaw, Michael H; Darcy, Phillip K.
Afiliação
  • Beavis PA; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
  • Slaney CY; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
  • Milenkovski N; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
  • Henderson MA; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
  • Loi S; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
  • Stagg J; Department of Immunology; Monash University ; Clayton, Australia ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie et Institut du Cancer de Montréal ; Montréal, QC Canada.
  • Kershaw MH; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia ; Department of Pathology; University of Melbou
  • Darcy PK; Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia ; Department of Pathology; University of Melbou
Oncoimmunology ; 4(11): e1046675, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26451321
ABSTRACT
In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália